Small molecule NADPH(NOX2)-agonists
Development of small molecule agonist of FPR/NOX2(NADPH oxidase)
for treatment of inflammatory, autoimmune and infectious diseases
2025-10-31
Concluding FET Open Horizon 2020 NeutroCure
The EU funderd FET project Neutrocure (Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation), has been completed.
In collaboration with projects partners including Swansea University, Redoxis and Friedrich-Alexander University Erlangen-Nuernberg, Pronoxis have affiliated third party of Redoxis, progressed our small molecule FPR/NOX2 agonist and strongly improved our technology and innovation, partnership readiness.
As major achievement Pronoxis secured EIC-Booster grant, completed EIC T2M venture building program, engaged with EIC business coach, secured additional national Innovation Agency funding, established a FPR1 agonist dedicated spin-off company, for treatments of severe and chronic infections and AMR and for this have gained support from national drug discovery program at ScilifeLAB.
2025-07-14
BOOST-iCURE Project
Secured support from EIC Booster grant to elevate outcomes within the FET initiative Neutrocure.
Pronoxis Boost-iCURE project focuses on developing small-molecule FPR1 agonists to boost innate immune responses against antimicrobial-resistant infections, improving the project's potential for clinical advancement, industry collaborations, and investor appeal.
The project will mature the innovation level of the project, by
the recently established spinoff company Inicure, which was established with support from the Gothenburg University incubator. In parallel, we will strengthen the technological maturation concerning chemistry lead optimisation at Swedish core facility ScilifeLAB and preclinical efficacy (in partnership with several international universities and institutes).
2024-10-01
Spinoff company Inicure AB
On October 1, 2024, Inicure, a spinoff company, was established. Founded by Peter Olofsson-Sal, Sara Malcus, and Johan Bylynd, Inicure AB received all IPR rights, a small molecule library, and ownership of project results and documentation from Pronoxis. The company is dedicated to developing FPR1 agonists for the treatment of infectious diseases, including antimicrobial resistance.
2024-02-29
Pronoxis ownerhip changes
The CRO company Redoxis have as result of more focused strategy for research services and expension as international recognised CRO, decided to sell the the founder of Pronoxis - Peter Olofsson-Sahl - all shares, ownership and rights to all IPR related to Pronoxis FPR/NOX2 poject.
Redoxis sold in February-2024 all the shares in Pronoxis to Inexius AB that is fully owned and controlled of Peter Olofsson-Sahl who is presently the sole owner of Pronoxis.
As inventor of Pronoxis small molecule project, Peter Olofsson-Sahl will continue the work together with academic partners with the EU program Neutrocure, research collaborators at Swansea University to explore the role of Pronoxis compounds in inflammation and infections.
2019-10-09
The FET Open Horizon 2020 project under the acronym NeutroCure, in which Redoxis together with Pronoxis is one of the partners, has been granted by the EU commission.
The project is focused on the development of smart amplifiers of reactive oxygen species to aberrant polymorphonuclear neutrophils for the treatment of inflammatory and autoimmune diseases, cancer and myeloablation and is a collaboration with academic groups in Germany, the United Kingdom, Ukraine, Spain and France. In the NeutroCure project, we will be able to combine our knowledge and interest in redox regulation of the immune system with our preclinical in vivo model platform.
Redoxis main role in the NeutroCure project will be preclinical efficacy and mode of action characterization. The project has a total budget of approximately 3 000 000 € over 5 years and Redoxis activities have been granted 400 000 €
